Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 ...

As you have seen, it has been a very active time at Eton. During the call, we will review fourth quarter results, provide additional color on the Hemangiol acquisition, and an update on our recent FDA ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2025 Earnings Call Transcript March 19, 2026 Eton Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.05 EPS, expectations were ...

Q4 2025 Earnings Call March 19, 2026 4:30 PM EDTCompany ParticipantsDavid Krempa - Chief Business OfficerSean Brynjelsen ...

A small survey in Germany found many men with severe hemophilia are not interested in gene therapy, which may suggest gaps in patient info.

Incyte has outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoingPhase 1: 83% ORR at RP2D and 100% ORR in the target Phase ...

DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 ---- Strong ...

This JetBlue fare is as basic as it gets, but holding Mosaic status could mitigate its toughest restrictions. This page includes information about these cards, currently unavailable on NerdWallet. The ...

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature ...

Whether you’re a seasoned fashion vet or rolling up fresh-faced to the menswear table, basics are the foundation of every great wardrobe. Yes, the best men's clothing brands are paid to push things ...